This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-37b / IL-1F7b Protein, His Tag
catalog :
ILB-H5141
quantity :
50 ug, 500 ug
price :
250 USD, 1200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ILB-H5141
product name :
Human IL-37b / IL-1F7b Protein, His Tag
quantity :
50 ug, 500 ug
price :
250 USD, 1200 USD
quantity & price :
$250/50ug,$1200/500ug (250ug × 2)
target :
IL-37
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human IL-37b, His Tag (ILB-H5141) is expressed from E.coli cells. It contains AA Val 46 - Asp 218 (Accession # AAH20637.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-37b, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-1 family member 7 (IL1F7b) ,a member of the IL-1 family, is aslo known as interleukin-37, interleukin-1 homolog 4 (IL-1H4), interleukin-1 zeta (IL-1 zeta) and interleukin-1-related protein, which can interact with SMAD3 and bind to IL18R1, but not to IL1R1, with lower affinity than IL18. IL1F7b is a suppressor of innate inflammatory and immune responses involved in curbing excessive inflammation. This function requires SMAD3. Therefore,IL1F7b can suppress, or reduce, proinflammatory cytokine production, including IL1A and IL6, as well as CCL12, CSF1, CSF2, CXCL13, IL1B, IL23A and IL1RN, but spare anti-inflammatory cytokines. Furthermore,IL1F7b can also inhibit dendritic cell activation.
References :
(1) Pan G., et al., 2001, Cytokine 13:1-7.
(2) Sharma S., et al., 2008, J. Immunol. 180:5477-5482.
(3) Nold M.F., et al., 2010, Nat. Immunol. 11:1014-1022.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments